Table 1 Demographic and clinical characteristics of patients.
Variable | Total (n = 101) | Romosozumab (n = 49) | Denosumab (n = 52) | p value |
|---|---|---|---|---|
Age (years) | 80.9 (3.9) | 81.3 (3.8) | 80.4 (4.1) | 0.240 |
BMI (kg/m2) | 21.1 (2.9) | 20.7 (3.0) | 21.5 (2.8) | 0.200 |
T-score | ||||
Lumbar spine | -2.6 (1.3) | -2.6 (1.3) | -2.6 (1.3) | 0.870 |
Total hip | -2.9 (1.0) | -3.0 (1.2) | -2.8 (0.9) | 0.270 |
Femoral neck | -3.4 (0.8) | -3.5 (0.8) | -3.2 (0.8) | 0.084 |
Prior use of active vitamin D | ||||
Yes | 14 (14) | 6 (12) | 8 (15) | 0.550 |
No | 86 (85) | 43 (88) | 43 (83) | |
Missing | 1 (1) | 0 (0) | 1 (2) | |
Smoking | ||||
Currently smoking | 4 (4) | 2 (4) | 2 (4) | 0.910 |
Not smoking | 89 (88) | 43 (88) | 46 (88) | |
Previously smoking | 5 (5) | 2 (4) | 3 (6) | |
Missing | 3 (3) | 2 (4) | 1 (2) | |
Brinkman index | 350.6 (285.5) | 475.0 (370.8) | 251.0 (178.9) | 0.270 |
Drinking | ||||
Yes | 3 (3) | 3 (6) | 0 (0) | 0.160 |
No | 93 (92) | 43 (88) | 50 (96) | |
Missing | 5 (5) | 3 (6) | 2 (4) | |
Exercise habit | ||||
Yes | 36 (36) | 21 (43) | 15 (29) | 0.140 |
No | 61 (60) | 25 (51) | 36 (69) | |
Missing | 4 (4) | 3 (6) | 1 (2) | |
Daily exercise duration (min) | 37.7 (26.1) | 36.1 (26.7) | 40.0 (26.1) | 0.670 |
Whether patients have ever had hip fracture | ||||
Yes | 6 (6) | 2 (4) | 4 (8) | 0.430 |
No | 91 (90) | 44 (90) | 47 (90) | |
Missing | 4 (4) | 3 (6) | 1 (2) | |
Blood examination | ||||
Serum-corrected calcium (mg/dL) | 8.3 (2.0) | 8.1 (2.1) | 8.4 (2.0) | 0.590 |
Serum phosphorus (mg/dL) | 3.6 (0.5) | 3.6 (0.4) | 3.6 (0.5) | 0.940 |
Serum creatinine (mg/dL) | 0.7 (0.1) | 0.7 (0.1) | 0.7 (0.1) | 0.410 |
Intact PTH (µg/mL) | 48.1 (20.9) | 47.2 (16.9) | 49.0 (24.0) | 0.670 |
PINP (µg/L) | 73.9 (40.1) | 80.0 (50.6) | 68.5 (27.4) | 0.180 |
TRACP-5b (mU/dL) | 596.3 (216.8) | 609.8 (233.9) | 584.4 (202.1) | 0.570 |
25OHD (ng/mL) | 20.4 (16.8) | 21.0 (19.1) | 19.8 (14.8) | 0.720 |
